Dallas, TX -- (SBWIRE) -- 02/04/2015 -- The report "Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome) – Pipeline Review, H1 2015" provides comprehensive information on the therapeutic development for Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome). Atypical hemolytic-uremic syndrome is a disease that primarily affects kidney function. Atypical hemolytic-uremic syndrome is caused by a genetic deficiency in one or more of the complement regulatory genes, which causes chronic uncontrolled complement activation. Atypical hemolytic-uremic syndrome is characterized by three major features related to abnormal clotting: hemolytic anemia, thrombocytopenia, and kidney failure. Complete Report is Available @ http://www.rnrmarketresearch.com/atypical-hemolytic-uremic-syndrome-nondiarrhea-associated-hemolytic-uremic-syndrome-pipeline-review-h1-2015-market-report.html.

It also reviews key players involved in the therapeutic development for Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome) and special features on late-stage and discontinued projects. Companies discussed in this Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome) Pipeline Review H1 2015 report include Adienne Pharma & Biotech, Alnylam Pharmaceuticals, Inc., ChemoCentryx, Inc., Omeros Corporation.

The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Order a Purchase copy of this report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=269559 . (This is a premium report priced at US$2000 for a single user License.)

Featured News & Press Releases
- Nov 20, 2014: ChemoCentryx's CCX168, an Orally Administered Complement C5a Receptor Inhibitor, Granted Orphan-Drug Designation in Atypical Hemolytic Uremic Syndrome Treatment by the FDA
- Nov 19, 2014: OMS721 Inhibits Thrombus Formation in Sera from aHUS Patients
- Apr 03, 2014: Investigational New Drug Application Cleared by FDA for OMS721 in Thrombotic Microangiopathies
- Mar 10, 2014: Omeros Announces Positive OMS721 Data in Serum from Patients with aHUS
- Mar 04, 2014: Omeros Submits IND to Advance OMS721 Phase 2 Clinical Program
- Feb 03, 2014: Omeros Announces Positive Data after Completion of Dosing in Phase 1 Clinical Trial with OMS721
- Dec 18, 2013: FDA Grants Orphan Drug Designation to Omeros' OMS721 for Complement-Mediated Thrombotic Microangiopathies
- Jun 20, 2013: Alnylam Scientists Present Preclinical Data With ALN-CC5 For Treatment Of Complement-mediated Diseases
- Jun 13, 2013: Omeros Obtains Regulatory Approval To Initiate Phase I Clinical Trial For Lead Antibody In MASP-2 Program
- May 28, 2013: Omeros Files Clinical Trial Application For Lead Antibody In MASP-2 Program 51

Table of Contents

List of Tables
Number of Products under Development for Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome), H1 2015 7
Number of Products under Development for Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome) - Comparative Analysis, H1 2015 8
Number of Products under Development by Companies, H1 2015 9
Comparative Analysis by Clinical Stage Development, H1 2015 10
Comparative Analysis by Early Stage Development, H1 2015 11
Products under Development by Companies, H1 2015 12
Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome) - Pipeline by Adienne Pharma & Biotech, H1 2015 13
Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome) - Pipeline by Alnylam Pharmaceuticals, Inc., H1 2015 14
Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome) - Pipeline by ChemoCentryx, Inc., H1 2015 15
Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome) - Pipeline by Omeros Corporation, H1 2015 16
Assessment by Monotherapy Products, H1 2015 17
Number of Products by Stage and Target, H1 2015 19
Number of Products by Stage and Mechanism of Action, H1 2015 21
Number of Products by Stage and Route of Administration, H1 2015 23
Number of Products by Stage and Molecule Type, H1 2015 25
Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome) Therapeutics - Recent Pipeline Updates, H1 2015 34
Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome) - Dormant Projects, H1 2015 41

Explore more reports on Pharmaceuticals industry at http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals.

About RnRMarketResearch.com
RnRMarketResearch.com is an online database of market research reports offer in-depth analysis of over 5000 market segments. The library has syndicated reports by leading market research publishers across the globe and also offer customized market research reports for multiple industries.